Four new polycyclic antibiotics, citreamicin θ A ( 1), citreamicin θ B ( 2), citreaglycon A ( 3), and dehydrocitreaglycon A ( 4), were isolated from marine-derived Streptomyces caelestis. The structures of these compounds were elucidated by 1D and 2D NMR spectra. All four compounds displayed antibacterial activity against Staphylococcus haemolyticus, Staphylococcus aureus, and Bacillus subtillis. Citreamicin θ A ( 1), citreamicin θ B ( 2) and citreaglycon A ( 3) also exhibited low MIC values of 0.25, 0.25, and 8.0 μg/mL, respectively, against methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300.
References
[1]
Gerwick, W.; Moore, B. Lessons from the past and charting the future of marine natural products drug discovery and chemical biology. Chem. Biol. 2012, 19, 85–98.
[2]
Bhakuni, D.S.; Rawat, D.S. Bioactive Marine Natural Products; Springer: New Delhi, India, 2005; pp. 13–17.
[3]
Seybold, U.; Kourbatova, E.V.; Johnson, J.G.; Halvosa, S.J.; Wang, Y.F.; King, M.D.; Ray, S.M.; Blumberg, H.M. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care associated blood stream infections. Clin. Infect. Dis. 2006, 42, 647–656, doi:10.1086/499815.
[4]
Cosgrove, S.E.; Sakoulas, G.; Perencevich, E.N.; Schwaber, M.J.; Karchmer, A.W.; Carmeli, Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin. Infect. Dis. 2003, 36, 53–59, doi:10.1086/345476.
[5]
Engemann, J.J.; Carmeli, Y.; Cosgrove, S.E.; Fowler, V.G.; Bronstein, M.Z.; Trivette, S.L.; Briggs, J.P.; Sexton, D.J.; Kaye, K.S. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 2003, 36, 592–598, doi:10.1086/367653.
[6]
Cosgrove, S.E.; Qi, Y.; Kaye, K.S.; Harbarth, S.; Karchmer, A.W.; Carmeli, Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: Mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 2005, 2, 166–174.
[7]
Klevens, R.M.; Morrison, M.A.; Nadle, J.; Petit, S.; Gershman, K.; Ray, S.; Harrison, L.H.; Lynfield, R.; Dumyati, G.; Townes, M.; et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298, 1763–1771.
[8]
Deresinski, S. Methicillin-Resistant Staphylococcus aureus: An evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. 2005, 40, 562–573, doi:10.1086/427701.
[9]
Leeb, M. Antibiotics: A shot in the arm. Nature 2004, 431, 892–893.
[10]
Maiese, W.M.; Lechevalier, M.P.; Lechevalier, H.A.; Korshalla, J.; Goodman, J.; Wildey, M.J.; Kuck, N.; Greenstein, M. LL-E19085 alpha, a novel antibiotic from Micromonospora citrea: Taxonomy, fermentation and biological activity. J. Antibiot. 1989, 42, 846–851, doi:10.7164/antibiotics.42.846.
[11]
Carter, G.T.; Nietsche, J.A.; Williams, D.R.; Borders, D.B. Citreamicins, novel antibiotics from Micromonospora citrea: Isolation, characterization, and structure determination. J. Antibiot. 1990, 43, 504–512, doi:10.7164/antibiotics.43.504.
[12]
Reich, M.F.; Lee, V.J.; Ashcroft, J.; Morton, G.O. An unusual cyclization product from the reaction of citreamicin η with sulfene. J. Org. Chem. 1993, 58, 5288–5290.
[13]
Hopp, D.C.; Milanowski, D.J.; Rhea, J.; Jacobsen, D.; Rabenstein, J.; Smith, C.; Romari, K.; Clarke, M.; Francis, L.; Irigoyen, M.; et al. Citreamicins with potent gram-positive activity. J. Nat. Prod. 2008, 71, 2032–2035.
[14]
Peoples, A.J.; Zhang, Q.; Millett, W.P.; Rothfeder, M.T.; Pescatore, B.C.; Madden, A.A.; Ling, L.L.; Moore, C.M. Neocitreamicins I and II, novel antibiotics with activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J. Antibiot. 2009, 61, 457–463.
[15]
Han, Z.; Xu, Y.; McConnell, O.; Liu, L.; Li, Y.; Qi, S.; Huang, X.; Qian, P. Two antimycin A analogues from marine-derived actinomycete Streptomyces lusitanus. Mar. Drugs 2012, 10, 668–676, doi:10.3390/md10030668.
[16]
Li, S.; Tian, X.; Niu, S.; Zhang, W.; Chen, Y.; Zhang, H.; Yang, X.; Zhang, W.; Li, W.; Zhang, S.; Ju, J.; Zhang, C. Pseudonocardians A–C, new diazaanthraquinone derivatives from a deep-sea Actinomycete Pseudonocardia sp. SCSIO 01299. Mar. Drugs 2011, 9, 1428–1439, doi:10.3390/md9081428.
[17]
Huang, H.; Yang, T.; Ren, X.; Liu, J.; Song, Y.; Sun, A.; Ma, J.; Wang, B.; Zhang, Y.; Huang, C.; Zhang, C.; Ju, J. Cytotoxic angucycline class glycosides from the deep sea actinomycete Streptomyces lusitanus SCSIO LR32. J. Nat. Prod. 2012, 75, 202–208, doi:10.1021/np2008335.
[18]
Schleissner, C.; Perez, M.; Losada, A.; Rodriguez, P.; Crespo, C.; Zuniga, P.; Fernandez, R.; Reyes, F.; De la Calle, F. Antitumor actinopyranones produced by Streptomyces albus POR-04-15-053 isolated from a marine sediment. J. Nat. Prod. 2011, 74, 1590–1596, doi:10.1021/np200196j.
[19]
Kondratyuk, T.P.; Park, E.J.; Yu, R.; Van Breemen, R.B.; Asolkar, R.N.; Murphy, B.T.; Fenical, W.; Pezzuto, J.M. Novel marine phenazines as potential cancer chemopreventive and anti-inflammatory agents. Mar. Drugs 2012, 10, 451–464, doi:10.3390/md10020451.
[20]
X-ray crystallogrphic analysis of compound 1: red crystal, 0.05 × 0.06 × 0.28, C30H23NO10, Mr = 557.49, monoclinic, space group P21/c, a = 15.307(3) ？, b = 7.9472(16) ？, c = 24.715(5) ？, β = 97.18(3)°, V = 2983.0(10) ？3, Z = 4, dx = 1.241 g/cm3, F(000) = 1160, μ(Cu Kα) = 0.795 mm？1. The data collection was performed on a Bruker SMART APEX-II using graphite-monochromated radiation (λ = 1.54178 ？), with 4797 unique reflections collected to θmax = 66.98°, where 2116 reflections were observed [F2 > 2σ(F2)]. The structures were solved by direct methods (SHELXTL, 2008) and refined by full-matrix least-squares on F2. The final R = 0.2224, Rw = 0.5021, and S = 1.848. The final model was not very accurate because of the small size of the crystal. The coordinates of the five-member ring and its side chain could not be determined very precisely.
[21]
Schneider, H.J.; Hacket, F.; Rüdiger, V.; Ikeda, H. NMR studies of cyclodextrins and cyclodextrin complexes. Chem. Rev. 1998, 98, 1755–1786, doi:10.1021/cr970019t.
[22]
Caccamese, S.; Manna, L.; Scivoli, G. Chiral HPLC separation and CD spectra of the C-2 diastereomers of naringin in grapefruit during maturation. Chirality 2003, 15, 661–667, doi:10.1002/chir.10262.
[23]
Person, R.V.; Monde, K.; Humpf, H.; Berova, N.; Nakanishi, K. A new approach in exciton-coupled circular dichroism (ECCD)—insertion of an auxiliary stereogenic center. Chirality 1995, 7, 128–135, doi:10.1002/chir.530070304.
[24]
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63.
[25]
Bozdogan, B.; Appelbaum, P.C. Oxazolidinones: Activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents 2004, 23, 113–119, doi:10.1016/j.ijantimicag.2003.11.003.
[26]
Patel, U.; Yan, Y.P.; Hobbs, F.W., Jr.; Kaczmarczyk, J.; Slee, A.M.; Pompliano, D.L.; Kurilla, M.G.; Bobkova, E.V. Oxazolidinones mechanism of action: Inhibition of the first peptide bond formation. J. Biol. Chem. 2001, 276, 37199–37205.
[27]
Sambrook, J.; Fritsch, E.F.; Maniatis, T. Molecular Cloning; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 1989; pp. 914–923.
[28]
Altschul, S.F.; Madden, T.L.; Sch？ffer, A.A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D.J. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res. 1997, 25, 3389–3402, doi:10.1093/nar/25.17.3389.
[29]
Schmitz, F.J.; Fluit, A.C.; Lückefahr, M.; Engler, B.; Hofmann, B.; Verhoef, J.; Heinz, H.P.; Hadding, U.; Jones, M.E. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 1998, 42, 807–810, doi:10.1093/jac/42.6.807.
[30]
Li, Y.; Xu, Y.; Liu, L.; Han, Z.; Lai, P.Y.; Guo, X.; Zhang, X.; Lin, W.; Qian, P.Y. Five new amicoumacins isolated from a marine-derived bacterium Bacillus subtilis. Mar. Drugs 2012, 10, 319–328, doi:10.3390/md10020319.
